**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[7]: C07D 211/26, 401/14, 413/14, A61K 31/445 — A1

(11) International publication number: WO 00/21931

(43) International publication date: 20 April 2000 (20.04.00)

(21) International application number: PCT/FR99/02355

(22) International filing date: 4 October 1999 (04.10.99)

(30) Data relating to the priority:
98/12,859 9 October 1998 (09.10.98) FR

(71) Applicant (for all designated States except US): SANOFI-SYNTHELABO [FR/FR]; 174, avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (US only): AULOMBARD, Alain [FR/FR]; 1, rue de la Manade, F-34970 Lattes (FR). EDMONDS-ALT, Xavier [FR/FR]; La Balajade, F-34980 Combaillaux (FR). PROIETTO, Vincenzo [IT/FR]; 1, cour du Merle, F-34680 Saint-Georges-d'Orques (FR). VAN BROECK, Didier [BE/FR]; 367, avenue du Champ des Moulins, F-34570 Murviel les Montpellier (FR).

(74) Representative: THOURET-LEMAITRE, Elisabeth; Sanofi-Synthelabo, 174, avenue de France, F-75013 Paris (FR).


(81) Designated states: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
With the International Search Report.

As printed

(54) Title: UREIDOPIPERIDINE DERIVATIVES AS SELECTIVE HUMAN $NK_3$ RECEPTOR ANTAGONISTS

(54) Titre: DERIVES D'UREIDOPIPERIDINE COMME ANTAGONISTES SELECTIFS DES RECEPTEURS $NK_3$ HUMAINS




(I)

(57) Abstract

The invention concerns compounds of formula (I) in racemic or optically pure form, methods for obtaining them and pharmaceutical compositions containing same. Said compounds are selective $NK_3$ receptor antagonists.

(57) Abrégé

La présente invention concerne les composés de formule (I) sous forme racémique ou optiquement pure, leurs procédés d'obtention et les compositions pharmaceutiques en contenant. Ces composés sont des antagonistes sélectifs du récepteur $NK_3$.